Arcturus Therapeutics Stock (NASDAQ: ARCT)

Arcturus Therapeutics (NASDAQ:ARCT) Stock

Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.

10 Alarming Facts About FLiRT And LB.1, The New COVID Variants Reshaping The Pandemic

Biotech

Equities

Large Cap

News

Health Care

General

ARCT

CSLLY

CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154, delivered superior immunogenicity compared to Pfizer&#39;s Comirnaty in a Phase 3 study, persisting for one year and at a lower dose.

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer&#39;s Comirnaty Shot, Even At Lower Doses

Earnings

Price Target

Small Cap

Markets

Analyst Ratings

Trading Ideas

Arcturus Therapeutics (NASDAQ: ARCT) closed the last trading session at $21.10, gaining 2.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide.

Does Arcturus Therapeutics Have the Potential to Rally 216.35% as Wall Street Analysts Expect?

Earnings Beats

Penny Stocks

ANTX

FULC

ILMN

AN2 Therapeutics (NASDAQ: ANTX), a clinical-stage company, leverages its boron chemistry platform to develop novel small molecule therapeutics to potentially treat various infectious diseases and cancer indications.

AN2 Therapeutics Plunges 66% in a Month: Here&#39;s Why

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics Holdings Inc

ARCTIC STAR EXPL CORP by Arctic Star Exploration Corp.

Arctic Star Exploration Corp

HC Wainwright &amp; Co. analyst Ed Arce reiterates Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) with a Buy and maintains $63 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Arcturus Therapeutics, Maintains $63 Price Target

Across the recent three months, 5 analysts have shared their insights on Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $58.6, along with a high estimate of $63.00 and a low estimate of $41.00. A decline of 6.98% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1739566861_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Arcturus Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$63.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Thomas Shrader</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$41.00</td>
<td>-</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$63.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$63.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$63.00</td>
<td>$63.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Arcturus Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Arcturus Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Arcturus Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Arcturus Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ARCT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Arcturus Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Arcturus Therapeutics's Background</h2>
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
<h3>Arcturus Therapeutics's Financial Performance</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Decline in Revenue: Over the 3 months period, Arcturus Therapeutics faced challenges, resulting in a decline of approximately -10.51% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -17.78%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Arcturus Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -2.65%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -1.82%, the company showcases effective utilization of assets.
Debt Management: With a high debt-to-equity ratio of 0.11, Arcturus Therapeutics faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Arcturus Therapeutics: 5 Analysts Share Their Views

European Commission Approves CSL And Arcturus Therapeutics' KOSTAIVE COVID-19 Vaccine, First sa-mRNA Vaccine Authorized For Adults In Europe

Meiji Seika Pharma and ARCALIS Co., Ltd. (Headquarters: Minami-soma City, Fukushima Prefecture; President: Satoshi Takamatsu) have been working together to establish an infrastructure that enables the integrated production of pharmaceuticals, from active ingredients to final products, within Japan. With this approval, ARCALIS's Minami-soma facilities and Meiji Seika Pharmatech Co., Ltd., a subsidiary of Meiji Seika Pharma, have been added as manufacturing sites. The technology transfer was managed and implemented by CSL Seqirus, the global licensor of KOSTAIVE&#xAE;. As a result, domestically produced products, with active pharmaceutical ingredients manufactured at ARCALIS's Minami-soma facilities and formulated at Meiji Seika Pharmatech, are now able to be shipped for commercial use in Japan.
About ARCALIS
ARCALIS, Inc. is a joint venture company between Axcelead Inc. and Arcturus Therapeutics Inc., which owns a group of world-class drug-discovery and healthcare platform companies. The company provides drug discovery support, as well as a contract development and manufacturing business (CDMO business), for mRNA medicines and vaccines.

Meiji Seika Pharma Secures Approval For Domestic Manufacturing Of KOSTAIVE, Japan's First Self-Amplifying mRNA COVID-19 Vaccine

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Arcturus Therapeutics, presenting an average target of $58.6, a high estimate of $63.00, and a low estimate of $41.00. Observing a downward trend, the current average is 6.98% lower than the prior average price target of $63.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1738072829_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Arcturus Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas Shrader</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$41.00</td>
<td>-</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$63.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$63.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$63.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$63.00</td>
<td>$63.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Arcturus Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Arcturus Therapeutics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Arcturus Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Arcturus Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ARCT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Arcturus Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Arcturus Therapeutics</h2>
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
<h3>Arcturus Therapeutics: Delving into Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Arcturus Therapeutics's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -10.51%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Arcturus Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -17.78% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Arcturus Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -2.65% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Arcturus Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of -1.82%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.11.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Arcturus Therapeutics: Insights From 5 Analyst Reviews

BTIG analyst Thomas Shrader initiates coverage on Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) with a Buy rating and announces Price Target of $41.

Initiation

BTIG Initiates Coverage On Arcturus Therapeutics with Buy Rating, Announces Price Target of $41

Arcturus Therapeutics Initiates Phase 1 H5N1 Flu Vaccine Trial

HC Wainwright &amp; Co. analyst Ed Arce maintains Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) with a Buy and maintains $63 price target.

HC Wainwright & Co. Maintains Buy on Arcturus Therapeutics, Maintains $63 Price Target

First participants initiated Phase 2 dosing for both CF and OTC deficiency in December 2024
Phase 2 interim data for both mRNA therapeutic programs on track for first half of 2025
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:<a href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the first CF and OTC deficiency participants initiated dosing in December 2024, in the Company's Phase 2 multiple ascending dose studies.
Each participant in the Phase 2 CF study (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06747858%3Fcond%3DCystic%2520Fibrosis%26term%3Darcturus%26rank%3D2&amp;esheet=54173841&amp;newsitemid=20250106386740&amp;lan=en-US&amp;anchor=NCT06747858&amp;index=1&amp;md5=bb147966a36afe3940f2894d41fe36ab">NCT06747858</a>) is expected to receive daily treatments of ARCT-032 over a period of 28 days.
The first OTC deficient participant receiving 0.5 mg/kg ARCT-810 initiated dosing in December 2024 in the United States. Each participant is expected to receive five intravenous infusions administered over two months. The Company previously announced the completion of the dosing phase (N = 8; 0.3 mg/kg) in a placebo-controlled European study enrolling OTC deficient individuals and expansion of the Phase 2 clinical program of ARCT-810 into the United States with an open-label multiple-dose study (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06488313&amp;esheet=54173841&amp;newsitemid=20250106386740&amp;lan=en-US&amp;anchor=NCT06488313&amp;index=2&amp;md5=34a550d7cb146fc9a95177ef24585dd6">NCT06488313</a>).

Arcturus Therapeutics Announces Initiation Of Dosing In Phase 2 Multiple Ascending Dose Studies For Cystic Fibrosis And Ornithine Transcarbamylase Deficiency; Phase 2 Interim Data For Both mRNA Therapeutic Programs On Track For First Half Of 2025

Cantor Fitzgerald analyst Pete Stavropoulos reiterates Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) from Overweight to Overweight.

Cantor Fitzgerald Reiterates Overweight on Arcturus Therapeuticsto Overweight

Meiji Seika Pharma Invests In ARCALIS, Expects To Enhance Japan's mRNA Vaccine Infrastructure

Arcturus Therapeutics Receives FDA Clearance To Begin H5N1 Pandemic Flu Vaccine Clinical Trial

Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(1.19) by 78.15 percent. The company reported quarterly sales of $41.673 million which beat the analyst consensus estimate of $36.597 million by 13.87 percent. This is a 7.68 percent decrease over sales of $45.140 million the same period last year.

Arcturus Therapeutics Q3 2024 GAAP EPS $(0.26) Beats $(1.19) Estimate, Sales $41.673M Beat $36.597M Estimate

Providing a diverse range of perspectives from bullish to bearish, 3 analysts have published ratings on Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Arcturus Therapeutics, revealing an average target of $65.33, a high estimate of $70.00, and a low estimate of $63.00. This current average reflects an increase of 6.23% from the previous average price target of $61.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1727816432_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Arcturus Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$63.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Lili Nsongo</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$63.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Arcturus Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Arcturus Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Arcturus Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Arcturus Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ARCT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Arcturus Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Arcturus Therapeutics's Background</h2>
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
<h3>Understanding the Numbers: Arcturus Therapeutics's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Arcturus Therapeutics displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 380.67%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -37.45%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Arcturus Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -6.59%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Arcturus Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -4.26%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Arcturus Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.12, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Unveiling 3 Analyst Insights On Arcturus Therapeutics

CSL Limited (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CSLLY#OTC">CSLLY</a>)&nbsp;and Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>)&nbsp;announced the results of a Phase 3 head-to-head study of ARCT-154, a self-amplifying (sa-mRNA) COVID-19 vaccine, compared to Pfizer Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b41089773/self-amplifying-mrna-covid-19-vaccine-demonstrates-superior-immune-response-compared-with-mrna-vac" rel="noreferrer noopener">shot Comirnaty</a>.
The study showed that the sa-mRNA COVID-19 vaccine maintained superior immunogenicity compared to the conventional mRNA vaccine Comirnaty&nbsp;for up to one year against Wuhan-Hu-1, Omicron&nbsp;BA.4-5&nbsp;and certain other variants, and at one-sixth the dose of the comparator&nbsp;(5 μg vs. 30 μg, respectively).
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39234193/arcturus-inhaled-mrna-therapeutic-in-cystic-fibrosis-study-highlights-potential-ami" rel="noreferrer noopener">Arcturus&#8217; Inhaled mRNA Therapeutic In Cystic Fibrosis Study Highlights Potential Amid Competitive Landscape: Analyst</a>.
The COVID-19 vaccine from this sa-mRNA platform targeted against the JN.1 variant is approved in Japan for immunization against COVID-19 in adults 18 years and older. It is being sold under the trade name Kostaive.
At Day 29, neutralizing antibodies (GMTs unadjusted) against the Wuhan-Hu-1 strain in ARCT-154 recipients (n = 378) were superior to those in the Comirnaty&nbsp;group (n = 374)
<ul>
<li>GMT = 5390 vs. 3738, a GMT ratio of 1.44. This advantage persisted through all time points.</li>
<li>At Day 361 (unadjusted), GMTs were 3396 and 1771 in ARCT-154 (n = 272) and Comirnaty (n = 266) groups, with a GMT ratio of 1.92.</li>
<li>Differences were also observed in responses against Omicron BA.4-5, with GMT ratios of 1.31 at Day 29 and 1.89 at Day 361.</li>
</ul>
Additional data presented by CSL and Arcturus finds that the bivalent formula ARCT-2301, developed on the same platform as ARCT-154, induces superior immunogenicity over conventional bivalent mRNA vaccine Comirnaty, which persists against key variants up to six months postvaccination.
<ul>
<li>Data from 930 participants showed that ARCT-2301 (n = 398) induced superior neutralizing antibody responses vs. Comirnaty (n = 405) against Omicron BA.4-5 (GMT ratio 1·49), and against Wuhan-Hu-1 (GMT ratio 1.45).</li>
<li>The difference persisted through six months with GMT ratios of 2.17 and 1.98, respectively.</li>
<li>Antibody responses against Omicron XBB.1.5 were also higher after ARCT-2301 vs. Comirnaty.</li>
</ul>
Price Action: ARCT stock is up 4.70% at $23.07 at last check Monday.
Image via Unsplash
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/41091774/prime-medicine-inks-cell-therapy-pact-with-bristol-myers-squibb-worth-over-3-5b-streamlines-pipel" target="_blank" rel="noreferrer noopener">Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline</a>.</li>
</ul>

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses

Press Releases

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference

Arcturus Therapeutics to Attend Upcoming Investor Conferences

Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency

Comments

Arcturus Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga